Spyre Therapeutics, Inc. (SYRE)
(Delayed Data from NSDQ)
$16.36 USD
+0.12 (0.74%)
Updated Sep 29, 2025 03:59 PM ET
After-Market: $16.40 +0.04 (0.24%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Spyre Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
SYRE 16.36 +0.12(0.74%)
Will SYRE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SYRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SYRE
Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know
How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%
SYRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect?
Other News for SYRE
Crossed Above 20 Day Moving Average appears for SYRE after 4.04% move
Fell Below 20 Day Moving Average appears for SYRE after 8.18% move
Deutsche Bank Initiates Coverage on Spyre Therapeutics (SYRE) with 'Buy' Rating | SYRE Stock News
This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Spyre Therapeutics initiated with a Buy at Deutsche Bank